Bosulif-Bosutinib-

Bosulif – Bosutinib

BOSULIF® (bosutinib) tablets are supplied for oral administration in two strengths: a 100 mg yellow, oval, biconvex, film-coated tablet debossed with “.Pfizer” on one side and “.100” on the other; and a 500 mg red, oval, biconvex, film-coated tablet debossed with “.Pfizer” on one side and “.500” on the other.

Each 100 mg BOSULIF tablet contains 103.40 mg of bosutinib monohydrate, equivalent to 100 mg of bosutinib; each 500 mg BOSULIF tablet contains 516.98 mg of bosutinib monohydrate, equivalent to 500 mg of bosutinib. The following inactive ingredients are included in the tablets: microcrystalline cellulose, croscarmellose sodium, poloxamer, povidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide yellow (for 100 mg tablet) and iron oxide red (for 500 mg tablet).

913total visits,4visits today

Reviews

There are no reviews yet.

Be the first to review “Bosulif – Bosutinib”